The Pharmaceutical Journal
Vol 270 No 7230 p14
4 January 2003

This page
Reprint
Photocopy

PDF* 80K

  Locum pharmacy
  Period-of-treatment fee
  Community pharmacy
  Repeat prescribing
  Wholesaling
  PI insurance
  Genetic research
  PILs
  Public health
  The Profession
  Branch meetings

Letters to the Editor

Genetic research

Information disclosed only with informed consent

From Mr K. K. Cheeseman

Your meeting report on the Genetics and Law conference (PJ, 7 December 2002, p822) reports me as saying: "... it is not usual for drug companies to disclose genetic information, and in most cases this would only be done with informed consent".

Lest there be any misunderstanding, I would like to make clear that disclosure of genetic information would only ever be done with the informed consent of the subject. This is certainly the policy of AstraZeneca and I believe it to represent the common standard in the industry. It is important that participants in genetic research are not led to believe that the research sponsors may disclose genetic information without their consent.

Kevin Cheeseman
Director of development pharmacogenetics
AstraZeneca

Send your letter to The Editor

Previous Topic (PI insurance)
Next Topic (PILs)